04:17 PM EST, 11/13/2025 (MT Newswires) -- Trevi Therapeutics ( TRVI ) reported a Q3 loss late Thursday of $0.08 per diluted share, narrowing from the loss of $0.13 a year earlier.

Analysts polled by FactSet expected a loss of $0.10.

The company ended the quarter with $194.9 million in cash, cash equivalents and marketable securities, providing a cash runway into 2028.